Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r AML patients selected for oral presentation on Thursday, June 12th – SAN DIEGO and TOKYO, May 14, 2025 (GLOBE NEWSWIRE) -- Kura Oncology ...

Merely click on TED and no fewer than 5,000 current presentation topics appear. One could see them live or view them online. Perhaps as a result of TED, more organizations now require oral ...

Aptose is developing TUS+VEN+AZA as a one-of-a-kind safe and mutation agnostic frontline triple drug therapy for newly diagnosed AML Oral presentation at EHA will include updated data at the 40 mg and ...

The data were from the Phase 2 clinical study of high-dose IBI302 (NCT05403749) to evaluate the efficacy, safety and dosing intervals in patients with nAMD over a one-year treatment period. A ...

SAN FRANCISCO and SUZHOU, China, June 1, 2025 /PRNewswire/ -- Innovent Biologics, Inc (Suzhou) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes ...

(MENAFN- GlobeNewsWire - Nasdaq) Late-breaking oral presentation to include full 12-month clinical data from INSPIRE registrational Phase 3 trial in addition to topline 18-month and 24-month data ...

The presentations will cover various topics related to the company's oral bradykinin B2 receptor antagonist, deucrictibant, highlighting research on its long-term safety, efficacy, and quality of ...

– Updated results with a later data cutoff, including endpoint analysis, will be presented at ASCO by lead investigator Heather Landau, MD, of Memorial Sloan Kettering Cancer Center – Immix ...

Results are being highlighted in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 30 - June 3, 2025, in Chicago, Illinois and virtually ...

Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r AML patients selected for oral presentation on Thursday, June 12th – – Updated dataset to be presented in oral presentation at EHA2025 ...